Maza Mauricio, Gage Julia C
Basic Health International, San Salvador, El Salvador.
Division of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda, MD, United States.
Prev Med. 2017 May;98:39-41. doi: 10.1016/j.ypmed.2016.12.029. Epub 2017 Feb 6.
The accumulated scientific evidence now provides ample support for HPV primary screening as a superior method for detecting cervical precancer and preventing cervical cancer. Approximately half of the global burden of cervical cancer could be reduced in lower-middle income countries where attempts to implement traditional cytology-based programs have not experienced successes. In these countries screening programs have struggled with poor screening and diagnostic test sensitivity, difficulties maintaining quality control and adequate population coverage. HPV testing is not only more accurate and reliable, but also requires less training, quality assurance and expensive personnel. Because these countries are especially vulnerable to economic, political and societal instabilities, HPV tests must become more affordable and accessible in order to enable Ministries of Health to make long-term resource commitments.
目前积累的科学证据充分支持将人乳头瘤病毒(HPV)初筛作为检测宫颈癌前病变和预防宫颈癌的一种更优方法。在中低收入国家,传统的基于细胞学的筛查项目实施效果不佳,而HPV初筛可减少全球约一半的宫颈癌负担。在这些国家,筛查项目面临筛查和诊断测试敏感性差、难以维持质量控制以及人口覆盖率不足等问题。HPV检测不仅更准确可靠,而且所需培训、质量保证和昂贵人力更少。由于这些国家特别容易受到经济、政治和社会不稳定因素的影响,HPV检测必须变得更经济实惠且易于获取,以便各国卫生部能够做出长期资源承诺。